Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib second-line monotherapy for unresectable or metastatic biliary tract cancer
ChiCTR2100052782Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in biliary cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 16-week progression-free survival rate. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100052782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052782.